The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II trial of VX15/2503 in children, adolescents, and young adults with relapsed or refractory solid tumors (ADVL1614).
 
Emily Gustava Greengard
No Relationships to Disclose
 
Robin Lesley Williams
No Relationships to Disclose
 
Xiaowei Liu
No Relationships to Disclose
 
Olga Militano
No Relationships to Disclose
 
Terrence Lee Fisher
Employment - Vaccinex
Stock and Other Ownership Interests - Vaccinex
Patents, Royalties, Other Intellectual Property - Patent author, Vaccinex, Inc.
 
Elizabeth E. Evans
Employment - Vaccinex
Stock and Other Ownership Interests - Vaccinex
Patents, Royalties, Other Intellectual Property - Inventor on following patents: Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent. U.S. Provisional Patent Application No. 62/473,731 Use of Semaphorin-4D inhibitory molecules in combination with an im (Inst)
 
Charles G. Minard
No Relationships to Disclose
 
Joel M. Reid
No Relationships to Disclose
 
Stephan D. Voss
No Relationships to Disclose
 
Stacey L. Berg
Research Funding - Other (Inst)
 
Elizabeth Fox
Research Funding - Ignyta (Inst); Novartis (Inst)
Other Relationship - Helsinn Therapeutics
 
Brenda Weigel
Travel, Accommodations, Expenses - Genentech; Lilly/ImClone; Nektar; Roche/Genentech; Roche/Genentech